BACKGROUND: The effects of soy isoflavones on prostate cancer may be concentration-dependent. The impact of soy supplementation on isoflavone concentrations in prostate tissues and serum remain unclear. OBJECTIVE: To assess and compare concentrations of soy isoflavones in prostate tissue and serum among 19 men with prostate cancer who had elected to undergo radical prostatectomy. METHODS: Participants were randomized to receive either daily soy supplements (82 mg/day aglycone equivalents) or placebos for 2 weeks (14 days) prior to surgery. Serum samples were obtained at the time of the surgery. Isoflavone concentrations were measured by HPLC/ESI-MS-MS. RESULTS: The median (25th, 75th percentile) total isoflavone concentration in the isoflavone-supplemented group was 2.3 micromol/L (1.2, 6.9) in the prostate tissue and 0.7 micromol/L (0.2, 1.2) in the serum. Total isoflavone concentrations in this group were an average of approximately 6-fold higher in prostate tissue compared to serum; the tissue versus serum ratio was significantly lower for genistein than daidzein, 4-fold versus 10-fold, P = 0.003. Tissue and serum levels of isoflavones among the placebo group were negligible with a few exceptions. CONCLUSIONS: The findings from the present study suggest that prostate tissue may have the ability to concentrate dietary soy isoflavones to potentially anti-carcinogenic levels. 2009 Wiley-Liss, Inc.
RCT Entities:
BACKGROUND: The effects of soy isoflavones on prostate cancer may be concentration-dependent. The impact of soy supplementation on isoflavone concentrations in prostate tissues and serum remain unclear. OBJECTIVE: To assess and compare concentrations of soy isoflavones in prostate tissue and serum among 19 men with prostate cancer who had elected to undergo radical prostatectomy. METHODS:Participants were randomized to receive either daily soy supplements (82 mg/day aglycone equivalents) or placebos for 2 weeks (14 days) prior to surgery. Serum samples were obtained at the time of the surgery. Isoflavone concentrations were measured by HPLC/ESI-MS-MS. RESULTS: The median (25th, 75th percentile) total isoflavone concentration in the isoflavone-supplemented group was 2.3 micromol/L (1.2, 6.9) in the prostate tissue and 0.7 micromol/L (0.2, 1.2) in the serum. Total isoflavone concentrations in this group were an average of approximately 6-fold higher in prostate tissue compared to serum; the tissue versus serum ratio was significantly lower for genistein than daidzein, 4-fold versus 10-fold, P = 0.003. Tissue and serum levels of isoflavones among the placebo group were negligible with a few exceptions. CONCLUSIONS: The findings from the present study suggest that prostate tissue may have the ability to concentrate dietary soy isoflavones to potentially anti-carcinogenic levels. 2009 Wiley-Liss, Inc.
Authors: L N Kolonel; J H Hankin; A S Whittemore; A H Wu; R P Gallagher; L R Wilkens; E M John; G R Howe; D M Dreon; D W West; R S Paffenbarger Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-08 Impact factor: 4.254
Authors: Dimitrios Spentzos; Christos Mantzoros; Meredith M Regan; Mary Ellen Morrissey; Stephen Duggan; Stacy Flickner-Garvey; Heather McCormick; William DeWolf; Steve Balk; Glenn J Bubley Journal: Clin Cancer Res Date: 2003-08-15 Impact factor: 12.531
Authors: Hesso Farhan; Kristiina Wähälä; Herman Adlercreutz; Heide S Cross Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2002-09-25 Impact factor: 3.205
Authors: Stephen Barnes; Jeevan Prasain; Tracy D'Alessandro; Ali Arabshahi; Nigel Botting; Mary Ann Lila; George Jackson; Elsa M Janle; Connie M Weaver Journal: Food Funct Date: 2011-05-09 Impact factor: 5.396
Authors: Antonino Battaglia; Gaëtan Devos; Guy Boeckx; Lieven Goeman; Lorenzo Tosco; Gert de Meerleer; Steven Joniau Journal: Curr Urol Date: 2020-10-13
Authors: Cornel J Phillip; Christopher K Giardina; Birdal Bilir; David J Cutler; Yu-Heng Lai; Omer Kucuk; Carlos S Moreno Journal: BMC Cancer Date: 2012-04-11 Impact factor: 4.430
Authors: Javad Sharifi-Rad; Cristina Quispe; Muhammad Imran; Abdur Rauf; Muhammad Nadeem; Tanweer Aslam Gondal; Bashir Ahmad; Muhammad Atif; Mohammad S Mubarak; Oksana Sytar; Oxana Mihailovna Zhilina; Ekaterina Robertovna Garsiya; Antonella Smeriglio; Domenico Trombetta; Daniel Gabriel Pons; Miquel Martorell; Susana M Cardoso; Ahmad Faizal Abdull Razis; Usman Sunusi; Ramla Muhammad Kamal; Lia Sanda Rotariu; Monica Butnariu; Anca Oana Docea; Daniela Calina Journal: Oxid Med Cell Longev Date: 2021-07-19 Impact factor: 6.543